Analysis of Risk Factors for Changes in the Renal Two-Dimensional Image in Gout Patients

References

• Christiansen SN, Østergaard M, Terslev L. Ultrasonography in gout: utility in diagnosis and monitoring. Clin Exp Rheumatol. 2018;36:61–67.
   PubMed Web of Science ®Google Scholar
• Castelblanco M, Lugrin J, Ehirchiou D, et al. Hydrogen sulfide inhibits NLRP3 inflammasome activation and reduces cytokine production both in vitro and in a mouse model of inflammation. J Biol Chem. 2018;293(7):2546–2557. doi:10.1074/jbc.M117.806869
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Choi HK, Joosten LAB, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69. doi:10.1038/s41572-019-0115-y
   PubMed Web of Science ®Google Scholar
• Le Y, Zhou X, Zheng J, et al. Anti-hyperuricemic effects of astaxanthin by regulating xanthine oxidase, adenosine deaminase and urate transporters in rats. Mar Drugs. 2020;18(12):610. doi:10.3390/md18120610
   PubMed Web of Science ®Google Scholar
• Johnson P, Loganathan C, Iruthayaraj A, Poomani K, Thayumanavan P. S-allyl cysteine as potent anti-gout drug: insight into the xanthine oxidase inhibition and anti-inflammatory activity. Biochimie 2018;154:1–9. doi:10.1016/j.biochi.2018.07.015
   PubMed Web of Science ®Google Scholar
• Tian Y, Lin L, Zhao M, Peng A, Zhao K. Xanthine oxidase inhibitory activity and antihyperuricemic effect of Moringa oleifera Lam. leaf hydrolysate rich in phenolics and peptides. J Ethnopharmacol. 2021;270:113808. doi:10.1016/j.jep.2021.113808
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821. doi:10.1056/NEJMra0800885
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Kang D-H, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183–1190. doi:10.1161/01.HYP.0000069700.62727.C5
   PubMed Web of Science ®Google Scholar
• Ko J, Kang HJ, Kim DA, et al. Uric acid induced the phenotype transition of vascular endothelial cells via induction of oxidative stress and glycocalyx shedding. FASEB J. 2019;33(12):13334–13345. doi:10.1096/fj.201901148R
   PubMed Web of Science ®Google Scholar
• Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010;49(1):141–146. doi:10.1093/rheumatology/kep364
   PubMed Web of Science ®Google Scholar
• Kuang-Hui Y, Chang-Fu K, Shue-Fen L, et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14(2):83. doi:10.1186/ar3806
   Web of Science ®Google Scholar
• Shavit L, Girfoglio D, Vijay V, et al. Vascular calcification and bone mineral density in recurrent kidney stone formers. Clin J Am Soc Nephrol. 2015;10(2):278–285. doi:10.2215/CJN.06030614
   PubMed Web of Science ®Google Scholar
• Lee YH, Song GG. Diagnostic accuracy of ultrasound in patients with gout: a meta-analysis. Semin Arthritis Rheum. 2018;47(5):703–709. doi:10.1016/j.semarthrit.2017.09.012
   PubMed Web of Science ®Google Scholar
• Bardin T, Nguyen QD, Tran KM, et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 2021;99(1):218–226. doi:10.1016/j.kint.2020.08.024
   PubMed Web of Science ®Google Scholar
• Joseph D, Philipp R, van Langevelde K, et al. Recent developments in advanced imaging in gout. Ther Adv Musculoskelet Dis. 2019;16:11.
   Google Scholar
• Tuhina N, Jansen TLTA, Nicola D, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789–1798. doi:10.1136/annrheumdis-2015-208237
   PubMed Web of Science ®Google Scholar
• Quaia E, Correas JM, Mehta M, Murchison JT, Gennari AG, van Beek EJR. Gray scale ultrasound, color Doppler ultrasound, and contrast-enhanced ultrasound in renal parenchymal diseases. Ultrasound Q. 2018;34(4):250–267. doi:10.1097/RUQ.0000000000000383
   PubMed Web of Science ®Google Scholar
• Wong C, Teitge B, Ross M, Young P, Robertson HL, Lang E. The accuracy and prognostic value of point-of-care ultrasound for nephrolithiasis in the emergency department: a systematic review and meta-analysis. Acad Emerg Med. 2018;25(6):684–698. doi:10.1111/acem.13388
   PubMed Web of Science ®Google Scholar
• Grenier N, Merville P, Combe C. Radiologic imaging of the renal parenchyma structure and function. Nat Rev Nephrol. 2016;12(6):348–359. doi:10.1038/nrneph.2016.44
   PubMed Web of Science ®Google Scholar
• Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380–390. doi:10.1038/s41584-020-0441-1
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Seminars in arthritis and rheumatism enters a new decade. Semin Arthritis Rheum. 2010;39(4):223. doi:10.1016/j.semarthrit.2009.11.001
   PubMed Web of Science ®Google Scholar
• Martin WJ, Harper JL. Innate inflammation and resolution in acute gout. Immunol Cell Biolm. 2010;88(1):15–19. doi:10.1038/icb.2009.89
   PubMed Web of Science ®Google Scholar
• Lai S, Dimko M, Galani A, et al. Early markers of cardiovascular risk in chronic kidney disease. Ren Fail. 2015;37(2):254–261. doi:10.3109/0886022X.2014.982489
   PubMed Web of Science ®Google Scholar
• Lu CC, Wu SK, Chung WS, Lin LH, Hung TW, Yeh CJ. Metabolic characteristics and renal dysfunction in 65 patients with tophi prior to gout. Clin Rheumatol. 2017;36(8):1903–1909. doi:10.1007/s10067-017-3663-0
   PubMed Web of Science ®Google Scholar
• Lu CC, Wu SK, Chen HY, Chung WS, Lee MC, Yeh CJ. Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout. J Rheumatol. 2014;41(9):1878–1883. doi:10.3899/jrheum.131240
   PubMed Web of Science ®Google Scholar
• Yoon-Jeong O, Won MK. Presence of tophi is associated with a rapid decline in the renal function in patients with gout. Sci Rep. 2021;11:5684. doi:10.1038/s41598-021-84980-6
   PubMed Web of Science ®Google Scholar
• Sun C, Qi X, Tian Y, Gao L, Jin H, Guo H. Risk factors for the formation of double-contour sign and tophi in gout. J Orthop Surg Res. 2019;14(1):239. doi:10.1186/s13018-019-1280-0
   PubMed Web of Science ®Google Scholar
• Huang Z, Liu X, Liu Y, et al. Clinical characteristics and risk factors of ulceration over tophi in patients with gout. Int J Rheum Dis. 2019;22:1052–1057.
   PubMed Web of Science ®Google Scholar
• Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11. doi:10.1016/j.ejim.2020.07.006
   PubMed Web of Science ®Google Scholar
• Major TJ, Dalbeth N, Stahl EA, Merriman TR. An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2018;14(6):341–353. doi:10.1038/s41584-018-0004-x
   PubMed Web of Science ®Google Scholar
• Liu J. Evaluation of serum cystatin C for diagnosis of acute rejection after renal transplantation. Transplant Proc. 2012;44(5):1250–1253. doi:10.1016/j.transproceed.2012.01.138
   PubMed Web of Science ®Google Scholar
• Mao W, Liu S, Wang K, et al. Cystatin C in evaluating renal function in Ureteral Calculi Hydronephrosis in adults. Kidney Blood Press Res. 2020;45:109–121.
   PubMed Web of Science ®Google Scholar
• Gharaibeh KA, Hamadah AM, El-Zoghby ZM, Lieske JC, Larson TS, Leung N. Cystatin C predicts renal recovery earlier than creatinine among patients with acute kidney injury. Kidney Int Rep. 2018;3(2):337–342. doi:10.1016/j.ekir.2017.10.012
   PubMed Web of Science ®Google Scholar
• Tang H, Zhao Y, Tan C, Liu Y. Significance of serum markers and urinary microalbumin in the diagnosis of Early renal damage in patients with gout. Clin Lab. 2021;67(5). doi:10.7754/Clin.Lab.2020.200722
   Web of Science ®Google Scholar
• Zhang QB, Zhu D, Wen Z, et al. High levels of serum uric acid, cystain C and lipids concentration and their clinical significance in primary gouty arthritis patients. Curr Rheumatol Rev. 2019;15(2):141–145. doi:10.2174/1573397114666180705095625
   PubMed Web of Science ®Google Scholar
• Xu LL, Gao W, Chen ZM, et al. Relationships between diabetic nephropathy and insulin resistance, inflammation, Trx, Txnip, CysC and serum complement levels. Eur Rev Med Pharmacol Sci. 2020;24:11700–11706.
   PubMed Web of Science ®Google Scholar
• Alberts A, Klingberg A, Wessig AK, et al. C-reactive protein (CRP) recognizes uric acid crystals and recruits proteases C1 and MASP1. Sci Rep. 2020;10(1):6391. doi:10.1038/s41598-020-63318-8
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016;4(24):481. doi:10.21037/atm.2016.12.27
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Colleran R, Kastrati A. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clin Chim Acta. 2018;476:130–138. doi:10.1016/j.cca.2017.11.026
   PubMed Web of Science ®Google Scholar
• Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27(1):127–133. doi:10.1161/01.ATV.0000251993.20372.40
   PubMed Web of Science ®Google Scholar
• Corti A, Belcastro E, Dominici S, Maellaro E, Pompella A. The dark side of gamma-glutamyltransferase (GGT): pathogenic effects of an ‘antioxidant’ enzyme. Free Radic Biol Med. 2020;160:807–819. doi:10.1016/j.freeradbiomed.2020.09.005
   PubMed Web of Science ®Google Scholar
• Obara R, Kamiya M, Tanaka Y. γ-Glutamyltranspeptidase (GGT)-activatable fluorescence probe for durable tumor imaging. Angew Chem Int Ed Engl. 2021;60(4):2125–2129. doi:10.1002/anie.202013265
   PubMed Web of Science ®Google Scholar
• Viljoen A, Chaudhry R, Bycroft J. Renal stones. Ann Clin Biochem. 2019;56(1):15–27. doi:10.1177/0004563218781672
   PubMed Web of Science ®Google Scholar
• Conway R, Murphy C-L, Madigan A, et al. Increased platelet reactivity as measured by plasma glycoprotein VI in gout. Platelets. 2018;29(8):821–826. doi:10.1080/09537104.2017.1366974
   PubMed Web of Science ®Google Scholar
• Elfishawi MM, Zleik N, Kvrgic Z, et al. The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol. 2018;45(4):574–579. doi:10.3899/jrheum.170806
   PubMed Web of Science ®Google Scholar
• Yu X, Wang T, Huang S, Zeng P. Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis. J Hum Genet. 2021;66(5):465–473. doi:10.1038/s10038-020-00863-0
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Jia X, et al. The anti-inflammatory properties of HDLs are impaired in gout. Clin Rheumatol. 2021;40(4):1525–1531. doi:10.1007/s10067-020-05374-z
   PubMed Web of Science ®Google Scholar
• Liang J, Jiang Y, Huang Y, et al. The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. Lipids Health Dis. 2020;19(1):31. doi:10.1186/s12944-020-1197-y
   PubMed Web of Science ®Google Scholar